RETAANE: what does the future hold?

Alcon has received an approvable letter from the FDA for RETAANE 15 mg (anecortave acetate depot suspension) for the treatment of wet age-related macular degeneration (AMD), however the letter advised that an additional clinical study would be required before approval is given.

In light of this, Alcon has decided not to proceed with the process, but it will continue with the Anecortave Acetate Risk-Reduction Trial (AART), which is investigating the ability of RETAANE to reduce the risk for the progression of dry AMD to wet AMD.

The trial has already completed enrolment and is expected to conclude within three years.